Moreover, a key factor of BER, the apurinic/apyrimidinic endonuclease 1 (APE1), has been underlined as a therapeutic target in NSCLC, as its inhibition resulted in excessive DNA damage and augmented tumor cell death in vitro and in vivo [20]. Here, APEX1 is linked to neoplasm.